USFDA inspection at Vadodara facility completed with no observations

Regulatory & Legal View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹817.00

prior close

₹808.40

announcement price

In-mkt

timing

Nifty Microcap 250market+0.1%-1.3% vs market

Pharmaceuticals peers, median of 173sector-0.1%-1.1% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.7

15m

+0.6

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2+0.1-1.3-0.1-1.1

Next day

+1.0-3.2+4.1-2.0+3.0

+0.9-3.3+4.2-2.0+2.9

+1.3-2.5+3.7-1.6+2.8

+3.4-0.9+4.3-1.0+4.4

+3.5-1.1+4.6-0.3+3.8

+3.3+0.6+2.7+0.3+3.0

15d

+2.6-1.4+4.0-2.8+5.5

-3.3-3.3-0.1-5.4+2.1

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharmaceuticals announced that the USFDA completed an unannounced onsite bioequivalence inspection at its Vadodara, Gujarat facility from August 31 to September 10, 2026. The inspection was closed with no Form 483 observations, indicating compliance with US regulatory standards. A clean outcome supports the company's ability to continue supplying products to the US market.

Likely market impact

Positive: clean USFDA inspection with zero observations strengthens US market access and regulatory credibility.